Literature DB >> 11182019

Cystic fibrosis.

P Robinson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11182019      PMCID： PMC1758774          DOI： 10.1136/thorax.56.3.237

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  31 in total

1.  The CF gene: 10 years on.

Authors:  D M Geddes; E W Alton
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

2.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

3.  Cystic fibrosis mortality in England and Wales and in Victoria, Australia 1976-80.

Authors:  P Phelan; E Hey
Journal:  Arch Dis Child       Date:  1984-01       Impact factor: 3.791

4.  Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).

Authors:  B Frederiksen; C Koch; N Høiby
Journal:  Pediatr Pulmonol       Date:  1999-09

5.  Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption.

Authors:  K Gaskin; D Gurwitz; P Durie; M Corey; H Levison; G Forstner
Journal:  J Pediatr       Date:  1982-06       Impact factor: 4.406

6.  Role of conventional physiotherapy in cystic fibrosis.

Authors:  J J Reisman; B Rivington-Law; M Corey; J Marcotte; E Wannamaker; D Harcourt; H Levison
Journal:  J Pediatr       Date:  1988-10       Impact factor: 4.406

7.  Immediate and long-term effects of chest physiotherapy in patients with cystic fibrosis.

Authors:  K J Desmond; W F Schwenk; E Thomas; P H Beaudry; A L Coates
Journal:  J Pediatr       Date:  1983-10       Impact factor: 4.406

8.  A multicenter comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis.

Authors:  C J Harrison; M I Marks; D F Welch; B B Sharma; D Baker; J Dice
Journal:  Pediatr Pharmacol (New York)       Date:  1985

9.  Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients.

Authors:  L O Lewin; P J Byard; P B Davis
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

10.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.

Authors:  O C Tablan; T L Chorba; D V Schidlow; J W White; K A Hardy; P H Gilligan; W M Morgan; L A Carson; W J Martone; J M Jason
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406
View more
  7 in total

Review 1.  The clinical value of neutrophil extracellular traps.

Authors:  Tim Lögters; Stefan Margraf; Jens Altrichter; Jindrich Cinatl; Steffen Mitzner; Joachim Windolf; Martin Scholz
Journal:  Med Microbiol Immunol       Date:  2009-08-04       Impact factor: 3.402

2.  Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

Authors:  A Clement; A Tamalet; E Leroux; S Ravilly; B Fauroux; J-P Jais
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

Review 3.  Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.

Authors:  Susan M Cheer; John Waugh; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2018-02-09

Review 5.  Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment.

Authors:  Luiz Vicente Ribeiro Ferreira da Silva Filho; Flavia de Aguiar Ferreira; Francisco José Caldeira Reis; Murilo Carlos Amorim de Britto; Carlos Emilio Levy; Otavio Clark; José Dirceu Ribeiro
Journal:  J Bras Pneumol       Date:  2013 Jun-Aug       Impact factor: 2.624

6.  Stenotrophomonas maltophilia: A marker of lung disease severity.

Authors:  Laura Berdah; Jessica Taytard; Sophie Leyronnas; Annick Clement; Pierre-Yves Boelle; Harriet Corvol
Journal:  Pediatr Pulmonol       Date:  2018-01-04

7.  Inhaled mannitol for cystic fibrosis.

Authors:  Sarah J Nevitt; Judith Thornton; Clare S Murray; Tiffany Dwyer
Journal:  Cochrane Database Syst Rev       Date:  2020-05-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.